Following an extensive international search, Dr. Anne-Claude Gingras was appointed as Director of the Lunenfeld-Tanenbaum Research Institute, and Vice President of Research for Sinai Health.
Throughout her career, Dr. Gingras has achieved significant national and international recognition. She is listed among the world’s top scientists and is Fellow of the Royal Society of Canada and an Associate Member of the European Molecular Biology Organization. Notable international awards include the Human Proteome Organization Discovery in Proteomics Science Award and the Molecular and Cellular Proteomics Lectureship Award.
At the national level, Dr. Gingras has been honoured with the Canadian National Proteomics Network-Tony Pawson Proteomics Award and the Charles W. Gowdey Distinguished Lecture Award, among others. She is a fellow of the Royal Society of Canada.
Sinai Health also recently announced the appointments of Drs. Susanna Mak and Daniel Schramek as Deputy Directors of Clinical and Discovery Research, respectively.
“Their alliance is exceptionally well-positioned to foster innovations that resonate not only within Sinai Health but across the global health-care landscape.”
Dr. Gary Newton, President and CEO of Sinai Health
Under Dr. Gingras’ leadership, Drs. Mak and Schramek will be instrumental in defining and executing the organization’s research strategy. Their focus will be on fostering discovery and clinical research integration across various specialties. Tasked with overseeing global talent recruitment and training opportunities enhancement, they will uphold an inclusive culture that embraces diverse backgrounds and perspectives at every career level.
“Drs. Mak and Schramek are accomplished leaders in their fields, bringing a wealth of knowledge in research, collaboration, and stewardship,” said Dr. Gary Newton, president and CEO of Sinai Health. “Coupled with Dr. Gingras’ visionary leadership, their alliance is exceptionally well-positioned to foster innovations that resonate not only within Sinai Health but across the global health-care landscape.”
Following an extensive international search, Dr. Anne-Claude Gingras was appointed as Director of the Lunenfeld-Tanenbaum Research Institute, and Vice President of Research for Sinai Health.
Throughout her career, Dr. Gingras has achieved significant national and international recognition. She is listed among the world’s top scientists and is Fellow of the Royal Society of Canada and an Associate Member of the European Molecular Biology Organization. Notable international awards include the Human Proteome Organization Discovery in Proteomics Science Award and the Molecular and Cellular Proteomics Lectureship Award.
At the national level, Dr. Gingras has been honoured with the Canadian National Proteomics Network-Tony Pawson Proteomics Award and the Charles W. Gowdey Distinguished Lecture Award, among others. She is a fellow of the Royal Society of Canada.
Sinai Health also recently announced the appointments of Drs. Susanna Mak and Daniel Schramek as Deputy Directors of Clinical and Discovery Research, respectively.
“Their alliance is exceptionally well-positioned to foster innovations that resonate not only within Sinai Health but across the global health-care landscape.”
Dr. Gary Newton, President and CEO of Sinai Health
Under Dr. Gingras’ leadership, Drs. Mak and Schramek will be instrumental in defining and executing the organization’s research strategy. Their focus will be on fostering discovery and clinical research integration across various specialties. Tasked with overseeing global talent recruitment and training opportunities enhancement, they will uphold an inclusive culture that embraces diverse backgrounds and perspectives at every career level.
“Drs. Mak and Schramek are accomplished leaders in their fields, bringing a wealth of knowledge in research, collaboration, and stewardship,” said Dr. Gary Newton, president and CEO of Sinai Health. “Coupled with Dr. Gingras’ visionary leadership, their alliance is exceptionally well-positioned to foster innovations that resonate not only within Sinai Health but across the global health-care landscape.”
